title: A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.
abstract: OBJECTIVE
  We sought to evaluate the efficacy of abciximab as adjunctive therapy to routine infarct-related artery (IRA) stenting.
  
  
  BACKGROUND
  The impact of abciximab on the efficacy of myocardial reperfusion and the outcome of patients with acute myocardial infarction (AMI) undergoing IRA stenting have not yet been defined.
  
  
  METHODS
  In a randomized trial, we assigned 400 patients with AMI to undergo IRA stenting alone or stenting plus abciximab. The primary end point was a composite of death, reinfarction, target vessel revascularization (TVR), and stroke at one month.
  
  
  RESULTS
  The incidence of the primary end point was lower in the abciximab group than in the stent only group (4.5% and 10.5%, respectively; p = 0.023), and randomization to abciximab was independently related to the risk of the primary end point (odds ratio 0.41, 95% confidence interval 0.17 to 0.97; p = 0.041). Early ST-segment resolution was more frequent in the abciximab group (85% vs. 68%, p < 0.001). Infarct size, as assessed by one-month technetium-99m sestamibi scintigraphy, revealed smaller infarcts in the abciximab group. At six months, the cumulative difference in mortality between the groups increased (4.5% vs. 8%), and the incidence of the composite of six-month death and reinfarction was lower in the abciximab group than in the stent only group (5.5% and 13.5%, respectively; p = 0.006). Six-month repeat TVR and restenosis rates were similar in the two groups.
  
  
  CONCLUSIONS
  Abciximab plus IRA stenting should be considered the routine reperfusion strategy in patients with AMI undergoing primary percutaneous mechanical revascularization, especially in high-risk patients.
authors.affiliation: Division of Cardiology, Careggi Hospital, Florence, Italy. carddept@tin.it
authors.forename: David
authors.initials: D
authors.lastname: Antoniucci
authors.forename: Alfredo
authors.initials: A
authors.lastname: Rodriguez
authors.forename: Albrecht
authors.initials: A
authors.lastname: Hempel
authors.forename: Renato
authors.initials: R
authors.lastname: Valenti
authors.forename: Angela
authors.initials: A
authors.lastname: Migliorini
authors.forename: Federico
authors.initials: F
authors.lastname: Vigo
authors.forename: Guido
authors.initials: G
authors.lastname: Parodi
authors.forename: Carlos
authors.initials: C
authors.lastname: Fernandez-Pereira
authors.forename: Guia
authors.initials: G
authors.lastname: Moschi
authors.forename: Antonio
authors.initials: A
authors.lastname: Bartorelli
authors.forename: Giovanni Maria
authors.initials: GM
authors.lastname: Santoro
authors.forename: Leonardo
authors.initials: L
authors.lastname: Bolognese
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
mesh_terms: D000077284:Abciximab; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D023903:Coronary Restenosis / Q000517:prevention & control; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D011877:Radionuclide Imaging; D015607:Stents; D017256:Technetium Tc 99m Sestamibi
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D017256:Technetium Tc 99m Sestamibi; D000077284:Abciximab